PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference HF 001/2003 PCT FOR FURTHER ACTION See Form PCT/IPEA/416									
International application No. International filing date (day/month/year) Priority date (day/month/year)									
PCT/EP2004/004033 16.04.2004 25.04.2003									
International Patent Classification (IPC) or national classification and IPC									
Applicant									
HF ARZNEIMITTELFORSCHUNG GMBH									
This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.									
2. This REPORT consists of a total of 5 sheets, including this cover sheet.									
3. This report is also accompanied by ANNEXES, comprising:									
a. (sent to the applicant and to the International Bureau) a total of sheets, as follows:									
sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or									
sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).									
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental									
Box.									
b (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s))									
, containing a sequence listing and/or tables									
related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).									
4. This report contains indications relating to the following items:									
Box No. I Basis of the report									
Box No. II Priority									
Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability									
Box No. IV Lack of unity of invention									
Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement									
Box No. VI Certain documents cited									
Box No. VII Certain defects in the international application									
Box No. VIII Certain observations on the international application									
Date of submission of the demand Date of completion of this report									
Name and mailing address of the IPEA/EP Authorized officer									
Facsimile No. Telephone No.									

Translation

International application No.
PCT/EP2004/004033

Box	No. I		Basis of the report					
1.			to the language, this report is based on the internation der this item.	al application in the language in which it was filed, unless otherwise				
	This report is based on translations from the original language into the following language which is the language of a translation furnished for the purposes of:							
			international search (Rule 12.3 and 23.1(b))					
		<u> </u>	publication of the international application (Rule 12.4)					
			international preliminary examination (Rule 55.2 and/o	or 55.3)				
2.	With regard to the elements of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report): the international application as originally filed/furnished							
		the de	scription:					
		pages	1-16	as originally filed/furnished				
		pages	•	received by this Authority on				
ļ		pages	*	received by this Authority on				
	\boxtimes	the cla	aims:					
Ì		nos.	1-15	as originally filed/furnished				
		nos.*		as amended (together with any statement) under Article 19				
		nos.*		received by this Authority on				
		nos.*		received by this Authority on				
Ì	\boxtimes		rawings:					
				as anisimally Glad/Granishad				
		sheets		as originally filed/furnished				
		sheet		received by this Authority on				
l		sheet	s*	received by this Authority on				
	a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.							
3.	3. The amendments have resulted in the cancellation of:							
Ì			the description, pages					
1			the claims, nos.					
ļ			the drawings, sheets/figs					
			the sequence listing (specify):					
1		\Box						
4.		This they	report has been established as if (some of) the amend	Iments annexed to this report and listed below had not been made, since iled, as indicated in the Supplemental Box (Rule 70.2(c)).				
1			the description, pages					
		\sqcap						
		\Box						
		\exists						
.	**	اب ر		anneaded "				
	If i	tem 4 a	pplies, some or all of those sheets may be marked "sup	perseaea				

International application No.
PCT/EP2004/004033

Box No. II	II Non-establishment of opinion with	n regard to novelty, inventive step and industrial applicability				
The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:						
	the entire international application	1				
\boxtimes	claims Nos. 13-15 (with regard	to industrial applicability)				
because	se:	40.45 (with record to industrial				
\boxtimes	the said international application, or the said relate to the following subject matter which	claims Nos. applicability) does not require an international preliminary examination (specify):				
	Claims 13-15 relate	to subject matter which, in the				
	opinion of this Auth	nority, falls under PCT				
	Rule 67.1(iv). Cons	sequently, no expert opinion has				
	been established in	respect of the industrial				
applicability of the subject matter of said claims						
	(PCT Article 34(4)(a)(i)).				
the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):						
	the claims, or said claims Nos.	are so inadequately supported				
_	by the description that no meaningful opin					
	no international search report has been esta	ablished for said claims Nos.				
the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Instructions in that:						
	the written form	has not been furnished				
		does not comply with the standard				
	the computer readable form	has not been furnished				
		does not comply with the standard				
	the tables related to the nucleotide and/or technical requirements provided for in An	r amino acid sequence listing, if in computer readable form only, do not comply with the nex C-bis of the Administrative Instructions.				
	See Supplemental Box for further details.					

International application No.
PCT/EP2004/004033

Bo	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
1.	Statement					
	Novelty ((N) Claims 1-15	_ YES			
		Claims	_ NO			
	Inventive	e step (IS) Claims 1-15	_ YES			
		Claims				
	Industria	applicability (IA) Claims 1-12	YES			
		Claims				
Ļ						
2.	Citations and explanations (Rule 70.7) 1.) Reference is made to the following documents:					
	D1: US-A-6 083 962 (LEVIN EDWARD D ET AL) 4 July					
}	2000 (2000-07-04)					
	D2: WO 99/17803 A (GARY MEDICAL CORP; GARY					
		DOUGLAS D (US)) 15 April 1999 (1999-04-15)				
		D3: WO 00/35279 A (NEWMAN MARY; SILVER ARCHIE				
(US); SANBERG PAUL (US); SHYTLE DO		(US); SANBERG PAUL (US); SHYTLE DOUGLAS (U)				
		22 June 2000 (2000-06-22)				
		D4: WO 00/48600 A (LOHMANN THERAPIE SYST LTS;				
1		ASMUSSEN BODO (DE); OPITZ KLAUS (DE); HILL)				
		24 August 2000 (2000-08-24)				
	2.) Document D1 describes using the combination of the					
	abused substance and an antagonist to treat abuse. Alcohol abuse is mentioned inter alia. Partial					
ŀ		substitution therapy (e.g. desoxypeganine) in				
		combination with mecylamine is not, however,				
	proposed.					
	Documents D2 and D3 describe using mecylamine to					
		treat alcohol abuse.				

International application No.
PCT/EP2004/004033

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Document D4 describes the use of desoxypeganine to treat alcohol abuse.

The applicant has shown that the combination of mecylamine and desoxypeganine produces a synergistic effect. This could not be foreseen by combining document D2 or D3 with document D4, in particular in view of the fact that those documents disclose two opposing treatment approaches.

Even taking into account D1, the effect of the combination could not be foreseen.

The subject matter of claim 1 is therefore novel (PCT Article 33(2)) and involves an inventive step (PCT Article 33(3)).

Claims 2-15 are dependent on claim 1 and therefore likewise meet the PCT requirements for novelty and inventive step.